The Neuroguard IEP Direct System from Contego Medical received US FDA premarket approval on November 10, 2026, making it the first transcarotid artery revascularization (TCAR) device to pair flow reversal with a built-in embolic filter. The approval rests on the PERFORMANCE III pivotal trial, where no patient had a stroke within 30 days and the one major adverse event was a cardiac death judged unlikely to be procedure-related. FDA also cleared the companion Neuroguard IEP Embolic Protection System through the 510(k) route.
Key takeaways on Neuroguard IEP Direct
- FDA granted PMA to the Neuroguard IEP Direct stent system and 510(k) clearance to its embolic protection system on November 10, 2026.
- The approach, which Contego calls TCAR-IEP, adds a 40-micron filter on top of flow reversal for “dual neuroprotection”.
- PERFORMANCE III: 146 pivotal patients at 27 centers; 0% stroke and a 0.7% 30-day composite of stroke, heart attack or death (intention-to-treat).
- The upper confidence limit of 3.78% was well under the 11% performance goal (P < .001).
- Mean flow-reversal time was 7.4 minutes, shorter than in earlier TCAR trials.
The problem it tries to solve
Carotid stenosis, a buildup of plaque in the main neck arteries, is a leading preventable cause of stroke. TCAR treats it through a small incision at the base of the neck: the surgeon temporarily reverses blood flow in the carotid so loose debris is pulled away from the brain while a stent is placed. It has grown quickly as a middle path between open surgery and stenting from the groin.
Flow reversal is not airtight. Doppler studies show flow toward the brain is not always fully reversed, and collateral flow from the external carotid can still carry tiny particles. Many dislodged fragments are smaller than 100 microns, below the pore size of standard filters and mesh-covered stents. Contego’s answer is to keep flow reversal and add a 40-micron filter downstream as a second catch.
How the system is built
- 3-in-1 catheter: a self-expanding nitinol stent, a prepositioned post-dilation balloon and the 40-micron filter on one 70 cm delivery system, cutting catheter exchanges.
- No venous line: blood drains by gravity into a collection bag placed about 20 cm below the access site, so no arteriovenous shunt or femoral vein puncture is needed.
- Pre-curved access sheath: designed for direct carotid entry.
- Time saving: co-principal investigator Dr. Sean Lyden of Cleveland Clinic estimates four to five minutes saved per case.
The same 3-in-1 stent system already had PMA from October 2024 for transfemoral and transradial carotid stenting, where it is distributed by Medtronic. The new approval brings it to the transcarotid route.
PERFORMANCE III results at a glance
| Measure | Result |
|---|---|
| Enrolled (lead-in + pivotal) | 178 (32 + 146), 26 US centers and 1 in France |
| Eligibility | Symptomatic stenosis 50% or more, or asymptomatic 70% or more |
| Mean stenosis | 82%; nearly all lesions moderately to severely calcified |
| 30-day stroke, MI or death (ITT, n=145) | 0.7% (95% CI 0.02% to 3.78%) |
| Per-protocol (n=144) | 0% |
| Strokes of any type | 0 |
| Cranial nerve injuries / stent thromboses | 0 / 0 |
| Technical and procedural success | 98.6% to 99.3% |
| Mean flow-reversal time | 7.4 min (vs 12.9 and 11.0 min in ROADSTER and ROADSTER 2) |
Data come from the 30-day results published in the Journal of Vascular Surgery and summarized by Cleveland Clinic, and from Contego’s approval announcement.
Why shorter flow reversal could matter
Vascular Quality Initiative registry data cited by the investigators link each extra minute of flow reversal beyond five minutes to a 2.7% rise in stroke risk, and reversal beyond 10 minutes to a 38% rise. By our calculation, PERFORMANCE III’s 7.4-minute mean is about 43% shorter than the 12.9 minutes in ROADSTER. That is an encouraging signal, though the investigators themselves warn that comparisons across separate trials are limited.
Limits of the evidence
This was a single-arm trial of 146 patients judged against a historical performance goal, not a randomized comparison with existing TCAR or surgery. Lyden has said the zero-stroke result needs confirmation in a larger registry. Long-term restenosis and stroke data are still to come, and more results are expected at the VEITHsymposium in New York from November 18 to 22. Lyden discloses consulting and research ties to Contego and other device makers.
Market context and the India view
Acumen Research and Consulting estimates the global embolic protection devices market at USD 627.8 million in 2023, reaching USD 1,234.1 million by 2032 at a 7.9% CAGR, with distal occlusion filters the largest product group and Asia-Pacific the fastest-growing region. The report page was last updated in July 2022, so treat the figures as indicative. No Indian regulatory filing for Neuroguard IEP Direct has been announced, so availability for Indian patients is unknown for now. Other recent cardiovascular device approvals include Abbott’s UltiSynq defibrillation lead and the Sonovein varicose vein system.
FAQ
What is TCAR-IEP?
Transcarotid artery revascularization with integrated embolic protection: carotid stenting through the neck that combines reversed blood flow with a fine filter to stop debris reaching the brain.
Is Neuroguard IEP Direct FDA approved?
Yes. FDA granted premarket approval on November 10, 2026, with 510(k) clearance for the companion embolic protection system.
How safe was it in the trial?
PERFORMANCE III reported no strokes at 30 days and a 0.7% rate of stroke, heart attack or death, from one cardiac death not attributed to the device.
How is it different from standard TCAR?
It adds a 40-micron filter to flow reversal, combines stent, balloon and filter in one catheter, and drains blood by gravity instead of through a vein.
Sources: Contego Medical announcement (November 10, 2026); PERFORMANCE III 30-day results, Journal of Vascular Surgery, via Cleveland Clinic. Market data: Acumen Research and Consulting. More in FDA Approvals. Not medical or investment advice. Last updated: November 12, 2026.

[…] argues protects patients after the procedure, not only during it. Earlier this week we reported on Contego’s Neuroguard IEP Direct approval, which takes a different route by building a filter into the system. Together the two decisions […]